Precision medicine applications in prostate cancer
- PMID: 29977347
- PMCID: PMC6024288
- DOI: 10.1177/1758835918776920
Precision medicine applications in prostate cancer
Abstract
Aided by developments in diagnostics and therapeutics, healthcare is increasingly moving toward precision medicine, in which treatment is customized to each individual. We discuss the relevance of precision medicine in prostate cancer, including gene targets, therapeutics and resistance mechanisms. We foresee precision medicine becoming an integral component of prostate cancer management to increase response to therapy and prolong survival.
Keywords: AR-V7; androgen deprivation therapy resistance; microsatellite instability; organic anion transporting polypeptide 1B3; precision medicine; sex determining region Y box2.
Conflict of interest statement
Conflict of interest statement: The authors declare that there is no conflict of interest.
Figures
References
-
- Huggins C, Stevens RE, Jr, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–223.
-
- Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297. - PubMed
-
- Anderson KM, Liao S. Selective retention of dihydrotestosterone by prostatic nuclei. Nature 1968; 219: 277–279. - PubMed
-
- Bruchovsky N, Wilson JD. The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. J Biol Chem 1968; 243: 5953–5960. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
